Monopar Therapeutics Inc (MNPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.37 Million) by net assets ($137.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Monopar Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Monopar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Monopar Therapeutics Inc (MNPR) shareholders funds for net asset value and shareholders' equity analysis.
Monopar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monopar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Kawin Technology Share-holding Co Ltd
SHG:688687
|
0.015x |
|
Asia Aviation Public Company Limited
BK:AAV
|
0.385x |
|
CJ Corp 4P Pref
KO:00104K
|
0.102x |
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
0.070x |
|
Manitowoc Company Inc
NYSE:MTW
|
0.040x |
|
Binh Minh Plastics JSC
VN:BMP
|
0.139x |
|
YTL Hospitality REIT
KLSE:5109
|
0.012x |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
0.024x |
Annual Cash Flow Conversion Efficiency for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Monopar Therapeutics Inc (MNPR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $137.83 Billion | $-12.20 Billion | -0.089x | +23.92% |
| 2024-12-31 | $55.04 Million | $-6.40 Million | -0.116x | +91.73% |
| 2023-12-31 | $5.59 Million | $-7.86 Million | -1.406x | -96.30% |
| 2022-12-31 | $10.09 Million | $-7.23 Million | -0.716x | -85.45% |
| 2021-12-31 | $18.94 Million | $-7.32 Million | -0.386x | -30.03% |
| 2020-12-31 | $15.69 Million | $-4.66 Million | -0.297x | -24.33% |
| 2019-12-31 | $12.63 Million | $-3.02 Million | -0.239x | +42.73% |
| 2018-12-31 | $6.92 Million | $-2.89 Million | -0.417x | -52.76% |
| 2017-12-31 | $9.62 Million | $-2.63 Million | -0.273x | +35.27% |
| 2016-12-31 | $2.83 Million | $-1.19 Million | -0.422x | -82.64% |
| 2015-12-31 | $2.75 Million | $-636.33K | -0.231x | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more